Interferon Alpha-2: Pre-Clinical and Clinical Evaluation

Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984

Nonfiction, Health & Well Being, Medical, Specialties, Oncology
Cover of the book Interferon Alpha-2: Pre-Clinical and Clinical Evaluation by , Springer US
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781461325796
Publisher: Springer US Publication: December 6, 2012
Imprint: Springer Language: English
Author:
ISBN: 9781461325796
Publisher: Springer US
Publication: December 6, 2012
Imprint: Springer
Language: English

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus­ cular and subcutaneous routes. Clinical toxicity principally involves the 'influen­ za like' syndrome previously seen with native interferons. Other important toxi­ cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non­ Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea­ ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna­ tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus­ cular and subcutaneous routes. Clinical toxicity principally involves the 'influen­ za like' syndrome previously seen with native interferons. Other important toxi­ cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non­ Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea­ ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna­ tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

More books from Springer US

Cover of the book Genomic Instability and Immortality in Cancer by
Cover of the book Drug Resistance by
Cover of the book Moisture Sensitivity of Plastic Packages of IC Devices by
Cover of the book Farewell Fossil Fuels by
Cover of the book Challenges in Caring by
Cover of the book Cerebral Sinus Thrombosis by
Cover of the book Redefining Families by
Cover of the book Aging in China by
Cover of the book Hate Crimes by
Cover of the book High Speed Serdes Devices and Applications by
Cover of the book Activity Systems Analysis Methods by
Cover of the book Atomic and Nuclear Physics by
Cover of the book Reducing the Risks for Substance Abuse by
Cover of the book Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development by
Cover of the book Drugs, Neurotransmitters, and Behavior by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy